Journal Home
Search for

Volume 42, Issue 4, Pages 297-303 (April 2010)


View previous. 12 of 18 View next.

Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression

Raffaella Lionettia, Giuseppe Tisoneb, Giampiero Palmieric, Cristiana Almerighia, Alessandra Anselmob, Laura Tariciottib, Ilaria Lencia, Linda De Lucab, Andrea Monacoa, Mario AngelicoaCorresponding Author Informationemail address

Received 24 June 2009; accepted 31 August 2009. published online 09 October 2009.

Abstract 

Background

Fibrosis in liver transplant recipients with recurrent HCV is fast, yet, different patterns of progression are recognized.

Aims

To investigate histological findings associated with maintenance ribavirin monotherapy in patients with recurrent HCV transplanted ≥4 years earlier.

Methods

14 recipients at high risk of progression (fibrosis progression rate >0.33 units/year and/or persistently elevated ALT) were assigned to receive ribavirin for 3 years. 11 patients at lower risk of progression (FPR ≤0.33 units/year and normal ALT) as controls. Biopsies were obtained yearly since transplant and 7 consecutive biopsies were evaluated.

Results

Improved necroinflammation (reduction ≥2 grading) was observed in 7 treated with ribavirin and 3 untreated patients, while 1 and 3 patients worsened respectively. Fibrosis improved (reduction >1 staging) in 2 ribavirin-treated patients, unchanged in 10 and worsened (increase ≥1 staging) in 2. Fibrosis progression decreased from 0.48±0.27 observed during the 3-year pre-treatment period to 0.04±0.31 units/year (p=0.003) during the 3 years of ribavirin. Among untreated fibrosis remained unchanged in 1 and worsened in 10 (p<0.001), yearly fibrosis progression rate increasing from 0.15±0.17 units/year to 0.42±0.39 units/year (p=0.10).

Conclusions

Maintenance ribavirin monotherapy delays fibrosis progression in high risk patients, offering an alternative strategy for those failing to respond to conventional treatment.

a Hepatology Unit, University of Rome “Tor Vergata”, Via Montpellier, 1, 00133 Rome, Italy

b Liver Transplant Unit, University of Rome “Tor Vergata”, Via Montpellier, 1, 00133 Rome, Italy

c Department of Pathological Anatomy, University of Rome “Tor Vergata”, Via Montpellier, 1 00133 Rome, Italy

Corresponding Author InformationCorresponding author at: Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università di Roma Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy. Tel.: +39 06 7259 6803; fax: +39 06 7259 6803.

PII: S1590-8658(09)00367-3

doi:10.1016/j.dld.2009.08.008


View previous. 12 of 18 View next.